* indicates required field
Length: 1
Source of Standard: SEER
Section Name: Stage/Prognostic Factors
Year Implemented: 2016
Version Implemented: 16
Record Types: A, M, C, I
XML NAACCR ID: metsAtDxOther
Parent XML Element: Tumor
Required Status:
NPCR Collect: . - No recommendations
CoC Collect: R - Required
SEER Collect: R - Required
CCCR Collect: R - Required
Description:
The six Mets at Dx-Metastatic Sites fields provide information on metastases for data analysis. This field identifies any type of distant involvement not captured in the Mets at Dx-Bone [1112], Mets at Dx-Brain [1113], Mets at Dx-Liver [1115], Mets at Dx-Lung [1116], and Mets at Dx-Distant LN [1114] fields. It includes involvement of other specific sites and more generalized metastases such as carcinomatosis. Some examples include but are not limited to the adrenal gland, bone marrow, pleura, malignant pleural effusion, peritoneum, and skin.
Rationale:
Information on site of metastatic disease at diagnosis has prognostic implications to survival among patients with initial late stage disease. Capturing data on where the patient’s metastatic lesions (including the number of locations) will be an important variable to include when looking at survival. Survival among metastatic patients is becoming increasingly important for cancer survivors.
Item Data Type:
digits
Allowable Values
0, 1, 2, 8, 9
Codes:
0 |
None; no other metastases |
|---|---|
1 |
Yes; distant metastases in known site(s) other than bone, brain, liver, lung or distant lymph nodes (Note: includes bone marrow involvement for lymphomas) |
2 |
Generalized metastases such as carcinomatosis |
8 |
Not applicable |
9 |
Unknown whether any other metastatic site or generalized metastases. Not documented in patient record. |